StockWire X
Get Free Alerts
StockWire X

Starpharma Hands the Chair to Russell Basser After 12 Years

Starpharma has finished its Board Chair transition, with Dr Russell Basser taking over from Rob Thomas AO after 12 years and David McIntyre stepping in as Deputy Chair.
By Josua Ferreira -
Starpharma (ASX: SPL) modern office interior as chair Dr Russell Basser appointed
Starpharma Holdings Ltd
Company Hub
Market Impact
5/10
  • Dr Russell Basser is now Starpharma's Chair and Mr David McIntyre is Deputy Chair, effective from the close of the 2026 Annual General Meeting.
  • Mr Rob Thomas AO retired as Chair after 12 years, as announced on 1 October 2026.
  • Mr Thomas stays on as a non-executive director after shareholders approved it at the meeting, which keeps continuity on the board.
  • The handover follows the Petalion majority stake, which lifted Starpharma's holding in the FAP-targeted cancer program from 22.5% to 66%.
Summarise with AI:
ChatGPTClaudePerplexity

Starpharma completes Chair transition as Dr Russell Basser takes the helm

Starpharma (ASX: SPL) advised on 6 November 2026 that Dr Russell Basser has assumed the role of Chair and Mr David McIntyre the role of Deputy Chair, effective from the close of the 2026 Annual General Meeting (AGM).

The appointments follow the retirement of Mr Rob Thomas AO as Chair after 12 years of service, as previously announced on 1 October 2026.

Starpharma Board Leadership Transition Map

  • Chair: Dr Russell Basser
  • Deputy Chair: Mr David McIntyre
  • Effective: from the close of the 2026 AGM
  • Outgoing Chair: Mr Rob Thomas AO, retired after 12 years as Chair

Rob Thomas AO stays on as a Non-Executive Director

Mr Thomas will continue as a non-executive director, following shareholder approval at the AGM, supporting continuity and an orderly Chair transition.

The Board thanked Mr Thomas for his distinguished service and significant contribution to Starpharma as Chair.

The leadership handover lands shortly after the Petalion majority stake lifted Starpharma’s holding in the FAP-targeted oncology program from 22.5% to 66%, giving the incoming Board a larger operating footprint to oversee.

Get Biotech and Healthcare News Before the Market Moves

Get FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to receive healthcare alerts the moment news breaks.


Frequently Asked Questions

Who is the new Chair of Starpharma?

Dr Russell Basser became Chair of Starpharma at the close of the 2026 Annual General Meeting, and Mr David McIntyre became Deputy Chair.

What does a company Chair do?

The Chair leads the board of directors, which oversees the company's management and strategy on behalf of shareholders.

Why did Rob Thomas leave the Starpharma Chair role?

Mr Rob Thomas AO retired as Chair after 12 years of service, as announced on 1 October 2026. He is staying on as a non-executive director.

When did the Starpharma Chair change take effect?

The change took effect from the close of the 2026 Annual General Meeting, and Starpharma confirmed it on 6 November 2026.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
LinkedIn
Companies Mentioned in Article
ASX:SPL
Topic Hubs
Biotech & Health Biotechnology Healthcare Life Sciences Pharmaceutical Research
Most Popular
Sponsored
ASX Stock News Categories
Sponsored

You May Also Like

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

  • Breaking ASX announcements delivered within minutes
  • Alerts delivered with expert analysis
  • Optional text alert for subscribers
  • No spam policy, unsubscribe any time
News
ASX Stock News
ASX Videos
Trending Topics▾
Capital MarketsRenewable EnergyMedical ImagingPortfolio ManagementASX 200ForexAll OrdinariesInflationInterest RatesAll Hub Pages
Analysis
Education
Free Alerts

About the Publisher

StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.

Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.

Use of Technology

We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.

While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.

Feedback and Accuracy

We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Editorial Standards

Disclaimer

StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).

StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.

Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.

StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.

Disclosure

StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.

If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Disclaimer